精神心理科

订阅

MedSci主页 / 所有栏目 / 精神心理科

强生的Spravato获FDA批准用于治疗抵抗性抑郁症

2019-03-06 不详 网络

抵抗性抑郁症谷氨酸受体esketamine
关注

FDA宣布批准强生公司的口服抗抑郁药Spravato（esketamine），用于治疗抵抗性抑郁症的成年患者。

FDA宣布批准强生公司的口服抗抑郁药Spravato（esketamine），用于治疗抵抗性抑郁症的成年患者。

FDA精神病学产品部主管Tiffany Farchione表示："出于安全考虑，该药物只能通过受限制的分销系统获得，并且必须在经过认证的医疗办公室进行管理。"FDA指出，Spravato存在镇静风险，患者必须在服用Spravato两小时后由医疗保健提供者进行监测。

这是对氯胺酮的s-对映体esketamine的首次批准，通过对大脑中的离子型谷氨酸受体NMDA受体结合发挥作用。

强生公司研发部全球负责人Mathai Mammen评论道："Spravato有可能改变治疗模式，将为三分之一的对现有疗法没有反应的抑郁症患者提供新的希望。"

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1794261, encodeId=23111e9426136, content=<a href='/topic/show?id=fb9f16641e9' target=_blank style='color:#2F92EE;'>#SPRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16641, encryptionId=fb9f16641e9, topicName=SPRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Mar 24 22:34:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665977, encodeId=8c0216659e72b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Sep 26 15:34:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794267, encodeId=57af1e94267c3, content=<a href='/topic/show?id=63f616642e6' target=_blank style='color:#2F92EE;'>#Spravato#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16642, encryptionId=63f616642e6, topicName=Spravato)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Oct 17 10:34:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 05 12:34:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 08 07:34:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362129, encodeId=766a362129c8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Wed Mar 06 18:03:58 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-24 sodoo

    #SPRA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1794261, encodeId=23111e9426136, content=<a href='/topic/show?id=fb9f16641e9' target=_blank style='color:#2F92EE;'>#SPRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16641, encryptionId=fb9f16641e9, topicName=SPRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Mar 24 22:34:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665977, encodeId=8c0216659e72b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Sep 26 15:34:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794267, encodeId=57af1e94267c3, content=<a href='/topic/show?id=63f616642e6' target=_blank style='color:#2F92EE;'>#Spravato#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16642, encryptionId=63f616642e6, topicName=Spravato)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Oct 17 10:34:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 05 12:34:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 08 07:34:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362129, encodeId=766a362129c8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Wed Mar 06 18:03:58 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-09-26 yige2012

    #抗性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1794261, encodeId=23111e9426136, content=<a href='/topic/show?id=fb9f16641e9' target=_blank style='color:#2F92EE;'>#SPRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16641, encryptionId=fb9f16641e9, topicName=SPRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Mar 24 22:34:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665977, encodeId=8c0216659e72b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Sep 26 15:34:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794267, encodeId=57af1e94267c3, content=<a href='/topic/show?id=63f616642e6' target=_blank style='color:#2F92EE;'>#Spravato#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16642, encryptionId=63f616642e6, topicName=Spravato)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Oct 17 10:34:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 05 12:34:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 08 07:34:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362129, encodeId=766a362129c8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Wed Mar 06 18:03:58 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-10-17 俅侠

    #Spravato#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1794261, encodeId=23111e9426136, content=<a href='/topic/show?id=fb9f16641e9' target=_blank style='color:#2F92EE;'>#SPRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16641, encryptionId=fb9f16641e9, topicName=SPRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Mar 24 22:34:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665977, encodeId=8c0216659e72b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Sep 26 15:34:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794267, encodeId=57af1e94267c3, content=<a href='/topic/show?id=63f616642e6' target=_blank style='color:#2F92EE;'>#Spravato#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16642, encryptionId=63f616642e6, topicName=Spravato)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Oct 17 10:34:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 05 12:34:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 08 07:34:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362129, encodeId=766a362129c8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Wed Mar 06 18:03:58 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-08-05 智者为医08

    #FDA批准#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1794261, encodeId=23111e9426136, content=<a href='/topic/show?id=fb9f16641e9' target=_blank style='color:#2F92EE;'>#SPRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16641, encryptionId=fb9f16641e9, topicName=SPRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Mar 24 22:34:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665977, encodeId=8c0216659e72b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Sep 26 15:34:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794267, encodeId=57af1e94267c3, content=<a href='/topic/show?id=63f616642e6' target=_blank style='color:#2F92EE;'>#Spravato#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16642, encryptionId=63f616642e6, topicName=Spravato)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Oct 17 10:34:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 05 12:34:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 08 07:34:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362129, encodeId=766a362129c8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Wed Mar 06 18:03:58 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-08 liuyong2980

    #强生#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1794261, encodeId=23111e9426136, content=<a href='/topic/show?id=fb9f16641e9' target=_blank style='color:#2F92EE;'>#SPRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16641, encryptionId=fb9f16641e9, topicName=SPRA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Mar 24 22:34:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665977, encodeId=8c0216659e72b, content=<a href='/topic/show?id=6f7d553159c' target=_blank style='color:#2F92EE;'>#抗性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55315, encryptionId=6f7d553159c, topicName=抗性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d5926034382, createdName=yige2012, createdTime=Thu Sep 26 15:34:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794267, encodeId=57af1e94267c3, content=<a href='/topic/show?id=63f616642e6' target=_blank style='color:#2F92EE;'>#Spravato#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16642, encryptionId=63f616642e6, topicName=Spravato)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Thu Oct 17 10:34:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839665, encodeId=7c0e1839665e9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 05 12:34:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Fri Mar 08 07:34:00 CST 2019, time=2019-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362129, encodeId=766a362129c8, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Wed Mar 06 18:03:58 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-06 329523732

    不错

    0

相关资讯

Lancet:认知行为疗法辅助治疗抵抗性抑郁症有效

　　仅1/3的抑郁症患者对抗抑郁药物产生完全应答，但是对于那些治疗抵抗性患者下一步的最佳治疗方式目前几乎尚无相关循证依据。日前，在线发表于《柳叶刀》（Lancet）杂志的一项研究对比了认知行为治疗(CBT)作为包括药物治疗在内的常规治疗的辅助疗法与单纯常规疗法治疗抵抗性抑郁症的相对疗效。结果证实，CBT作为常规疗法的一种辅助疗法是有效的，有助于缓解这类人群的抑郁症状。 与抑郁症相关的拓展